Sector
PharmaceuticalsOpen
₹20.28Prev. Close
₹19.32Turnover(Lac.)
₹0.71Day's High
₹20.28Day's Low
₹19.7152 Week's High
₹4652 Week's Low
₹17.35Book Value
₹18.69Face Value
₹10Mkt Cap (₹ Cr.)
10.29P/E
17.79EPS
1.14Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 5.09 | 5.09 | 5.09 | 5.09 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3.83 | 2.97 | 2.2 | 2.84 |
Net Worth | 8.92 | 8.06 | 7.29 | 7.93 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 14.07 | 12.81 | 15.14 | 10.93 |
yoy growth (%) | 9.84 | -15.37 | 38.5 | -16.6 |
Raw materials | -7.41 | -6.6 | -9.27 | -6.49 |
As % of sales | 52.7 | 51.56 | 61.24 | 59.41 |
Employee costs | -1.17 | -0.96 | -0.77 | -1 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | -0.1 | 0.15 | 1.27 | -0.37 |
Depreciation | -1.27 | -0.65 | -0.32 | -0.37 |
Tax paid | -0.1 | -0.1 | -0.28 | -0.07 |
Working capital | 1.26 | -0.7 | 0.27 | -0.17 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 9.84 | -15.37 | 38.5 | -16.6 |
Op profit growth | 59.97 | -13.01 | -1,703.87 | -112.59 |
EBIT growth | -24.45 | -65.93 | -920.72 | -135.96 |
Net profit growth | 399.81 | -95.17 | -322.01 | -368.51 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.3 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,613.75 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,512.75 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.2 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,225.7 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Sanjay Sethi
Chairman & Non Executive Dir.
Sudhir Sethi
Independent Non Exe. Director
Abhinav Naik
Independent Non Exe. Director
Shreya Saraf
Company Sec. & Compli. Officer
Neha Sharma
133 Kanchan Bag,
Madhya Pradesh - 452001
Tel: 91-731-25076375/3046366
Website: http://www.beryldrugs.com
Email: [email protected]
19/20 Jaferbhoy Ind,
1st Floor Makwana Rd, Marol Naka,
Mumbai - 400 059
Tel: 91-022-28594060
Website: www.adriotcorporate.com
Email: [email protected]
Summary
Beryl Drugs Limited, based in Indore, was incorporated on August 24, 1993. The Company acquired the running business of M/s Flora and Fauna Remedies Limited on December 15, 1993. The Shares of Company...
Read More
Reports by Beryl Drugs Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.